Grifols (NASDAQ:GRFS) Reaches New 12-Month Low – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $7.37 and last traded at $7.3750, with a volume of 326041 shares trading hands. The stock had previously closed at $7.64.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Weiss Ratings upgraded shares of Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Zacks Research downgraded shares of Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Grifols has a consensus rating of “Reduce” and a consensus price target of $10.00.

Grifols Trading Down 3.9%

The firm has a market cap of $5.00 billion, a PE ratio of 38.71, a PEG ratio of 0.30 and a beta of 0.65. The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16. The stock’s fifty day simple moving average is $8.05 and its two-hundred day simple moving average is $8.60.

Grifols (NASDAQ:GRFS) last announced its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. The business had revenue of $2.32 billion for the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. On average, sell-side analysts forecast that Grifols, S.A. will post 1.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Grifols

A number of institutional investors have recently made changes to their positions in the company. Bank of Montreal Can lifted its holdings in shares of Grifols by 3,205.1% during the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock valued at $30,017,000 after buying an additional 2,922,540 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Grifols by 383.7% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after buying an additional 2,221,633 shares during the period. Norges Bank bought a new position in shares of Grifols during the 4th quarter valued at $18,139,000. Brandes Investment Partners LP lifted its holdings in shares of Grifols by 6.3% during the 4th quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock valued at $289,422,000 after buying an additional 1,838,727 shares during the period. Finally, Barclays PLC lifted its holdings in shares of Grifols by 132.6% during the 4th quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock valued at $22,764,000 after buying an additional 1,387,783 shares during the period.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.